ABSTRACT The location of injection and vaccine deposition in ovo is known to be critical to the efficacy of Marek's disease (MD) vaccine protection against MD viral challenge. Vaccine deposition into the amniotic sac or a s.c. or i.m. site of the embryo is required for MD vaccine efficacy. Vaccine deposition into the air cell or allantoic fluid results in chicks that are not adequately protected against subsequent MD viral challenge. A study was conducted in 2 commercial broiler hatcheries to evaluate the ability of 2 in ovo injection systems, the Embrex Inovoject system (Pfizer Poultry Health, Research Triangle Park, NC) and the Intelliject system (Avitech, Salisbury, MD; distributed by Merial Ltd., Gainesville, GA) to deliver a vaccine approved for use in ovo accurately and properly. A standard MD vaccine diluent mixed with a protein-staining dye was delivered through each machine to simulate in ovo vaccination. The location of the dye within the egg determined whether the vaccine was delivered correctly. Each egg was also evaluated for normal embryo development (normal eggs). Correct vaccine delivery included eggs in which the vaccine was injected into the amniotic sac or into s.c. or i.m. regions of the embryo. Incorrect vaccine delivery was defined as delivery into the air cell; allantoic sac; any combinations including air cell or allantois; the abdominal, cranial, orbital, or thoracic cavities of the embryo; or no vaccine delivery at all. In hatchery 1 (Chick Master, Newton, MS) 1,171 normal eggs were processed through the Inovoject system and 1,138 eggs were processed by the Intelliject system. The Inovoject system correctly vaccinated 94.62% of the normal eggs as compared with 61.16% delivery accuracy of normal eggs with the Intelliject system. In hatchery 2 (Jamesway Super J, Magee, MS) 926 normal eggs were processed by the Inovoject system and 910 normal eggs were processed by the Intelliject system. The Inovoject system correctly vaccinated 91.04% of the normal eggs, whereas the Intelliject system correctly vaccinated 71.98% of the normal eggs. The results of this study clearly demonstrate that the Inovoject system accurately delivered in ovo vaccine at a significantly higher rate than the Intelliject system.
INTRODUCTION
The first research on the in ovo administration of vaccines was completed by Sharma and Witter (1983) . Subsequent work demonstrated that in ovo administration of Marek's disease (MD) vaccines HVT, SB-1, and CVI988 to late-stage chicken embryos was safe and would induce earlier immunity than posthatch administration (Sharma et al., 1984; Zhang and Sharma, 2001 ). Because of these results, the practice of in ovo vaccination was moved from the laboratory to commercial poultry hatcheries (Gildersleeve et al., 1993; Sarma et al., 1995) . Today, in ovo vaccination occurs routinely in many commercial broiler hatcheries around the world, particularly in the Americas, Japan, Australia, and parts of Europe.
The process and technique used to administer in ovo vaccines is critical. Delivering vaccine to an incorrect in ovo site can lead to an ineffective vaccination, thus reducing the benefits normally seen by vaccinating in ovo. The complexity of the in ovo route is often underappreciated, and this is attributable in part to the 5 embryonic compartments that can be accessed by the needle during the in ovo vaccination process: the air cell (AC), allantoic sac (AL), amniotic fluid (AM), embryo body (EM), and yolk sac. Furthermore, EM injections can be s.c., i.m., intracranial, intraorbital, or intraabdominal, with the latter 3 causing excessive embryo trauma. The efficacy of a vaccine and the safety to the embryo can be affected by the embryonic compartment into which it is deposited. Wakenell et al. (2002) showed that efficacy against MD virus challenge was dependent on the site of MD vaccine delivery in ovo. The MD vaccine was not effective when delivered onto the AC or into the AL. The highest efficacy was found in the AM, with a 94.4% protective index, and in the EM, with a 93.9% protective index. Protective efficacy in chicks with vaccine injected into the AC or AL was less than 50%. This work showed that the vaccine must be injected deep enough into the egg to be delivered into the amnion, which includes the AM and EM. When vaccines are delivered to the AM, the vaccine is imbibed, breathed in, or both by the embryo before hatching. The more developmentally mature embryos in the population are injected in the right breast area. Embryo body delivery is normal; however, penetration too deep into the egg at any stage of development can cause excessive trauma to the embryo.
MATERIALS AND METHODS

In Ovo Injection Equipment
Technical representatives from both in ovo equipment manufacturers prepared their respective machines and ensured proper function of the equipment during the conduct of each trial. The equipment differed by site because a specific injector design was required for each incubation system. The trial conducted at the Chick Master hatchery (Newton, MS) compared the Embrex Inovoject Systems Vaccine Saver CM 108 design (serial no. V 2954, Pfizer Poultry Health, Research Triangle Park, NC) with the Avitech Intelliject CM 162 design (serial no. 00035, Avitech, Salisbury, MD). The trial conducted at the Jamesway hatchery (Magee, MS) compared the Embrex Inovoject Systems Vaccine Saver JW 84 design (serial no. V 2252A) with the Intelliject JW 168 design (serial no. 00063).
Eggs
Eggs from Cobb breeder flocks were selected by incubator tray from the egg incubation racks in the same format and position as they were incubated. In the Jamesway hatchery, 4 incubator trays (84 eggs/ tray, 336 eggs/age group) were randomly selected from 3 separate breeder flocks of differing ages. Eggs were injected in ovo at their normal transfer age (Jamesway incubation system: d 18 + 7 h of incubation). A total of 1,008 eggs were used per injection system.
In the Chick Master hatchery, 6 trays (54 eggs/tray, 324 eggs/age group) were randomly selected from 4 separate breeder flocks of differing ages. Eggs were injected in ovo at their normal transfer age (Chick Master incubation system: d 19 + 1 h of incubation). A total of 1,296 eggs were used for the evaluation of each injection system.
Vaccination Procedure
The Inovoject systems used in these studies are designed to deliver 50 μL of vaccine per injection cycle to each egg determined as viable, whereas the Intelliject systems are designed to deliver 100 μL to all eggs during each cycle. The test eggs were injected immediately before the beginning of the normal transfer and injection time. Each vaccine system was purged of alcohol with sterile saline, and then test vaccine was added. The sanitation system for both machines functioned as normal, using each manufacturer's recommended chlorinated sanitizer solution. The test vaccine bag contained standard Marek's vaccine diluent and a proteinstaining dye without the inclusion of any vaccine.
Embryo Euthanasia and Vaccine Deposition Evaluation
After injection was completed, test eggs, while still in the original incubation flats, were bagged by treatment, killed using CO 2 gas, and stored for 4 h at low temperature. After euthanasia, eggs were carefully dissected and vaccine deposition site was determined. Each egg was also evaluated for normal embryo development. Eggs were segregated by embryo development status into abnormal eggs (upside down, early dead, mid dead, late dead, cracked shell, malformed or malpositioned embryo, rotten, and infertile) and normal eggs (normal embryo development). Only normally developed embryos were included in the site of injection analysis.
Experimental Design
Two separate trials were conducted in 2 commercial broiler hatcheries. One hatchery used the Chick Master incubation system and the other used the Jamesway Super-J incubation system. Because of differences in the design of the incubation tray that nests the eggs during embryonic development, specific egg injection machines from each manufacturer were required for each incubation system (Chick Master or Jamesway). Additionally, other application differences existed between the 2 types of egg injection systems (Pfizer's Embrex Inovoject system or Avitech's Intelliject system), hence the purpose for this evaluation. Both hatcheries used egg injection equipment specifically designed for use by either the Chick Master or Jamesway incubation system. Other than the egg flat configuration and difference in time of injection dictated by either the Jamesway or Chick Master incubation system, the protocol for vaccine application and injection site determination were identical between the 2 sites.
Correct injections in ovo for optimal MD efficacy are defined as delivery of vaccine into the AM and EM or EM-AM injections (Wakenell et al., 2002) . For the purposes of this study, incorrect injections were defined as AC, AL, combinations that included AC or AL, and all incorrect embryo sites (intracranial, intraorbital, intraabdominal) . No attempts were made to quantify or differentiate volume of vaccine delivered to multiple sites in ovo; therefore, suboptimal doses or partial delivery to correct sites in ovo were considered incorrect applications. Correct injections included only complete delivery of individual vaccine dispensed into the correct site in ovo. The egg was considered the experimental unit in a generalized randomized complete block design with flock as the blocking factor. Correct vs. incorrect injections were analyzed by exact conditional logistic regression, with flock as a stratifying variable and treatment as a factor (SAS/STAT Version 9.1.3 Service Pack 3, SAS Institute Inc., Cary, NC). In terms of adjustment for multiple comparisons, the overall treatment effect for site of injection was evaluated using a Fisher's protected least significant difference type approach for comparisons for each site without adjustment. Statistical significance was determined with P ≤ 0.05.
RESULTS AND DISCUSSION
Two separate analyses were completed, one for each type of incubation system involved, because myriad random effects were related to each hatchery and respective incubation system. In the Chick Master hatchery, 1,296 eggs were injected by each injection system. Of those, 1,171 normal eggs were injected by the Inovoject system and 1,138 normal eggs were injected by the Intelliject system. Although randomized at injection, the difference in the number of normal eggs between the 2 groups was primarily due to fertility variation from tray to tray associated with eggs from the oldest breeder flock. Only live normal embryos at injection time were included in the evaluation. The Inovoject system correctly injected a higher percentage of normal eggs (P ≤ 0.0001) than the Intelliject system ( Table 1 ). The same model was then applied to each specific category (vs. all others). The Intelliject system was significantly higher (P ≤ 0.0001; Table 2 ) in all categories of incorrect vaccine deposition (AC, AL, AC or AL combinations, and EM incorrect), whereas the Inovoject system performed significantly better in all categories of correct vaccine deposition (AM and EM proper) except for the combination AM and EM injections, for which the Intelliject system delivered significantly more than the Inovoject system (P ≤ 0.0001).
In the Jamesway hatchery, 1,008 eggs were injected by each injection system. Of those, 926 normal eggs were injected by the Inovoject system and 910 normal eggs were injected by the Intelliject system. As in trial 1, the Inovoject system (Table 3) had significantly more correct vaccinations (AM) in ovo (P ≤ 0.0001) than the Intelliject system, except for injections of EM proper, for which there was no significant difference (P > 0.5984) and injections of AM-EM proper, for which the Intelliject system had significantly (P ≤ 0.0114) more proper injections than the Inovoject system. The Intelliject system (Table 3 ) delivered significantly (P ≤ 0.0001) more incorrect vaccine placements (AC, AC or AL combinations, and EM incorrect) when compared with the Inovoject system, except for AL (P > 0.4308) and the combination AM-EM incorrect injections (P > 0.9999), for which there was no significant difference. Total eggs  41  29  19  181  78  1,153  21  50  136  601  2,309 a,b Numbers within a column lacking a common superscript differ (P ≤ 0.05). 1 AC = air cell; AL = allantoic sac; AM = amniotic fluid; EM = embryo body.
With respect to accuracy of vaccine deposition by the Inovoject system in the Chick Master hatchery vs. the JW hatchery, differences could be seen that were caused by embryo age and egg setter tray design. The egg tray configuration and stability of the egg in the tray varied between the 2 incubation systems, with the Jamesway incubation tray allowing eggs to deviate more than the Chick Master incubation tray along the upright axis. The design of the Chick Master incubation tray kept eggs in a very tight, upright position and did not allow egg movement laterally while the eggs were being turned in the incubator. In addition, embryos in the Chick Master hatchery were 18 h older at transfer compared with those in the Jamesway hatchery. The optimal time to inject eggs, developmentally, is the physiological stage between when the stalk of the yolk sac is beginning its ascent into the abdomen and the head is tucked under the wing up until external pipping is initiated. The optimal target site for uniform automated in ovo vaccination is the AM or right breast area of the developing embryo. Injections into the cranium, ocular space, and abdomen of the embryo are considered off-target injections and are a result of misalignment of injectors with the eggshell surface. These delivery sites in ovo are not desirable for MD vaccine delivery to the late-stage developing embryo and are incorrect applications. As the embryo increases in size late in incubation, the likelihood of injecting the embryo proper increases and, with correct injector-to-egg alignment, results in targeted delivery to the right breast area. Why the delivery results of the Intelliject system did not reflect this is unknown.
This study shows the large variability in accuracy of vaccine deposition, depending on the in ovo vaccination system used. Previous work done by Islam et al. (2001) and Wakenell et al. (2002) demonstrated that vaccine protection against challenge was dependent on the vaccine delivery site. The vaccine must be injected deep enough into the egg to be delivered into the amnion, which includes the AM and EM. When delivered to the AM, the vaccine is imbibed, breathed in, or both by the embryo before hatching. The MD vaccination delivered via the AL results only in significantly lower viremia and does not adequately protect against challenge, whereas delivery to the AC shows no embryo access to the vaccine, thus no vaccinal response. As the embryo matures and begins the hatching process (internal and external pipping), more embryos in the population are injected either s.c. or i.m. into the right breast area. Embryo body delivery during in ovo vaccination is normal; however, penetration too deep into the egg and embryo during late-stage development can cause excessive trauma to the embryo. Therefore, use of an in ovo injection system that does not deliver vaccine to the correct embryonic site would compromise embryo safety and vaccine performance. The objective of commercial in ovo vaccination is to vaccinate every viable embryo safely and uniformly. To accomplish this objective, a commercial in ovo vaccination device must administer vaccine to sites that result in the greatest safety and efficacy for the vaccine delivered. In this study, the Inovoject system was significantly better at meeting that objective. a,b Numbers within a column lacking a common superscript differ (P ≤ 0.05). 1 AC = air cell; AL = allantoic sac; AM = amniotic fluid; EM = embryo body.
